

FIRST REGULAR SESSION

HOUSE BILL NO. 793

93RD GENERAL ASSEMBLY

INTRODUCED BY REPRESENTATIVES NOLTE (Sponsor), PARSON, SATER,
COOPER (158) AND FLOOK (Co-sponsors).

Read 1st time March 15, 2005 and copies ordered printed.

STEPHEN S. DAVIS, Chief Clerk

2028L.011

AN ACT

To repeal section 195.017, RSMo, and to enact in lieu thereof one new section relating to the scheduling of controlled substances.

Be it enacted by the General Assembly of the state of Missouri, as follows:

Section A. Section 195.017, RSMo, is repealed and one new section enacted in lieu thereof, to be known as section 195.017, to read as follows:

195.017. 1. The department of health and senior services shall place a substance in Schedule I if it finds that the substance:

(1) Has high potential for abuse; and

(2) Has no accepted medical use in treatment in the United States or lacks accepted safety for use in treatment under medical supervision.

2. Schedule I:

(1) The controlled substances listed in this subsection are included in Schedule I;

(2) Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the existence of these isomers, esters, ethers and salts is possible within the specific chemical designation:

(a) Acetyl-alpha-methylfentanyl;

(b) Acetylmethadol;

(c) Allylprodine;

(d) Alphacetylmethadol;

(e) Alphameprodine;

EXPLANATION — Matter enclosed in bold-faced brackets [thus] in the above bill is not enacted and is intended to be omitted from the law. Matter in **bold-face** type in the above bill is proposed language.

- 16 (f) Alphamethadol;
- 17 (g) Alpha-methylfentanyl;
- 18 (h) Alpha-methylthiofentanyl;
- 19 (i) Benzethidine;
- 20 (j) Betacetylmethadol;
- 21 (k) Beta-hydroxyfentanyl;
- 22 (l) Beta-hydroxy-3-methylfentanyl;
- 23 (m) Betameprodine;
- 24 (n) Betamethadol;
- 25 (o) Betaprodine;
- 26 (p) Clonitazene;
- 27 (q) Dextromoramide;
- 28 (r) Diampromide;
- 29 (s) Diethylthiambutene;
- 30 (t) Difenoxin;
- 31 (u) Dimenoxadol;
- 32 (v) Dimepheptanol;
- 33 (w) Dimethylthiambutene;
- 34 (x) Dioxaphetyl butyrate;
- 35 (y) Dipipanone;
- 36 (z) Ethylmethylthiambutene;
- 37 (aa) Etonitazene;
- 38 (bb) Etoxidine;
- 39 (cc) Furethidine;
- 40 (dd) Hydroxypethidine;
- 41 (ee) Ketobemidone;
- 42 (ff) Levomoramide;
- 43 (gg) Levophenacymorphan;
- 44 (hh) 3-Methylfentanyl;
- 45 (ii) 3-Methylthiofentanyl;
- 46 (jj) Morpheridine;
- 47 (kk) MPPP;
- 48 (ll) Noracymethadol;
- 49 (mm) Norlevorphanol;
- 50 (nn) Normethadone;
- 51 (oo) Norpipanone;

52 (pp) Para-fluorofentanyl;

53 (qq) PEPAP;

54 (rr) Phenadoxone;

55 (ss) Phenampromide;

56 (tt) Phenomorphan;

57 (uu) Phenoperidine;

58 (vv) Piritramide;

59 (ww) Proheptazine;

60 (xx) Properidine;

61 (yy) Propiram;

62 (zz) Racemoramide;

63 (aaa) Thiofentanyl;

64 (bbb) Tilidine;

65 (ccc) Trimeperidine;

66 (3) Any of the following opium derivatives, their salts, isomers and salts of isomers
67 unless specifically excepted, whenever the existence of these salts, isomers and salts of isomers
68 is possible within the specific chemical designation:

69 (a) Acetorphine;

70 (b) Acetyldihydrocodeine;

71 (c) Benzylmorphine;

72 (d) Codeine methylbromide;

73 (e) Codeine-N-Oxide;

74 (f) Cyprenorphine;

75 (g) Desomorphine;

76 (h) Dihydromorphine;

77 (i) Drotebanol;

78 (j) Etorphine; (except Hydrochloride Salt);

79 (k) Heroin;

80 (l) Hydromorphenol;

81 (m) Methyldesorphine;

82 (n) Methyldihydromorphine;

83 (o) Morphine methylbromide;

84 (p) Morphine methylsulfonate;

85 (q) Morphine-N-Oxide;

86 (r) Myrophine;

87 (s) Nicocodeine;

- 88 (t) Nicomorphine;
89 (u) Normorphine;
90 (v) Pholcodine;
91 (w) Thebacon;
92 (4) Any material, compound, mixture or preparation which contains any quantity of the
93 following hallucinogenic substances, their salts, isomers and salts of isomers, unless specifically
94 excepted, whenever the existence of these salts, isomers, and salts of isomers is possible within
95 the specific chemical designation:
96 (a) 4-bromo-2,5-dimethoxyamphetamine;
97 (b) 4-bromo-2, 5-dimethoxyphenethylamine;
98 (c) 2,5-dimethoxyamphetamine;
99 (d) 2,5-dimethoxy-4-ethylamphetamine;
100 (e) 4-methoxyamphetamine;
101 (f) 5-methoxy-3,4-methylenedioxyamphetamine;
102 (g) 4-methyl-2,5-dimethoxy amphetamine;
103 (h) 3,4-methylenedioxyamphetamine;
104 (i) 3,4-methylenedioxymethamphetamine;
105 (j) 3,4-methylenedioxy-N-ethylamphetamine;
106 (k) N-hydroxy-3, 4-methylenedioxyamphetamine;
107 (l) 3,4,5-trimethoxyamphetamine;
108 (m) Alpha-ethyltryptamine;
109 (n) Bufotenine;
110 (o) Diethyltryptamine;
111 (p) Dimethyltryptamine;
112 (q) Ibogaine;
113 (r) Lysergic acid diethylamide;
114 (s) Marijuana; (Marihuana);
115 (t) Mescaline;
116 (u) Parahexyl;
117 (v) Peyote, to include all parts of the plant presently classified botanically as *Lophophora*
118 *Williamsii* Lemaire, whether growing or not; the seeds thereof; any extract from any part of such
119 plant; and every compound, manufacture, salt, derivative, mixture or preparation of the plant,
120 its seed or extracts;
121 (w) N-ethyl-3-piperidyl benzilate;
122 (x) N-methyl-3-piperidyl benzilate;
123 (y) Psilocybin;

- 124 (z) Psilocyn;
125 (aa) Tetrahydrocannabinols;
126 (bb) Ethylamine analog of phencyclidine;
127 (cc) Pyrrolidine analog of phencyclidine;
128 (dd) Thiophene analog of phencyclidine;
129 (ee) 1-(1-(2-thienyl)cyclohexyl) pyrrolidine;
130 (5) Any material, compound, mixture or preparation containing any quantity of the
131 following substances having a depressant effect on the central nervous system, including their
132 salts, isomers and salts of isomers whenever the existence of these salts, isomers and salts of
133 isomers is possible within the specific chemical designation:
134 (a) Gamma hydroxybutyric acid;
135 (b) Mecloqualone;
136 (c) Methaqualone;
137 (6) Any material, compound, mixture or preparation containing any quantity of the
138 following substances having a stimulant effect on the central nervous system, including their
139 salts, isomers and salts of isomers:
140 (a) Aminorex;
141 (b) Cathinone;
142 (c) Fenethylline;
143 (d) Methcathinone;
144 (e) (+)cis-4-methylaminorex ((+)cis-4,5-dihydro- 4-methyl-5-phenyl-2-oxazoline);
145 (f) N-ethylamphetamine;
146 (g) N,N-dimethylamphetamine;
147 (7) A temporary listing of substances subject to emergency scheduling under federal law
148 shall include any material, compound, mixture or preparation which contains any quantity of the
149 following substances:
150 (a) N-(1-benzyl-4-piperidyl)-N-phenyl-propanamide (benzylfentanyl), its optical isomers,
151 salts and salts of isomers;
152 (b) N-(1-(2-thienyl)methyl-4-piperidyl)-N-phenylpropanamide (thenylfentanyl), its
153 optical isomers, salts and salts of isomers;
154 **(8) Khat, to include all parts of the plant presently classified botanically as catha**
155 **edulis, whether growing or not; the seeds thereof; any extract from any part of such plant;**
156 **and every compound, manufacture, salt, derivative, mixture, or preparation of the plant,**
157 **its seed or extracts.**
158 3. The department of health and senior services shall place a substance in Schedule II
159 if it finds that:

- 160 (1) The substance has high potential for abuse;
161 (2) The substance has currently accepted medical use in treatment in the United States,
162 or currently accepted medical use with severe restrictions; and
163 (3) The abuse of the substance may lead to severe psychic or physical dependence.
164 4. The controlled substances listed in this subsection are included in Schedule II:
165 (1) Any of the following substances whether produced directly or indirectly by extraction
166 from substances of vegetable origin, or independently by means of chemical synthesis, or by
167 combination of extraction and chemical synthesis:
168 (a) Opium and opiate and any salt, compound, derivative or preparation of opium or
169 opiate, excluding apomorphine, thebaine-derived butorphanol, dextrophan, nalbuphine,
170 nalmefene, naloxone and naltrexone, and their respective salts but including the following:
171 a. Raw opium;
172 b. Opium extracts;
173 c. Opium fluid;
174 d. Powdered opium;
175 e. Granulated opium;
176 f. Tincture of opium;
177 g. Codeine;
178 h. Ethylmorphine;
179 i. Etorphine hydrochloride;
180 j. Hydrocodone;
181 k. Hydromorphone;
182 l. Metopon;
183 m. Morphine;
184 n. Oxycodone;
185 o. Oxymorphone;
186 p. Thebaine;
187 (b) Any salt, compound, derivative, or preparation thereof which is chemically
188 equivalent or identical with any of the substances referred to in this subdivision, but not
189 including the isoquinoline alkaloids of opium;
190 (c) Opium poppy and poppy straw;
191 (d) Coca leaves and any salt, compound, derivative, or preparation of coca leaves, and
192 any salt, compound, derivative, or preparation thereof which is chemically equivalent or identical
193 with any of these substances, but not including decocainized coca leaves or extractions which
194 do not contain cocaine or ecgonine;
195 (e) Concentrate of poppy straw (the crude extract of poppy straw in either liquid, solid

- 196 or powder form which contains the phenanthrene alkaloids of the opium poppy);
- 197 (2) Any of the following opiates, including their isomers, esters, ethers, salts, and salts
- 198 of isomers, whenever the existence of these isomers, esters, ethers and salts is possible within
- 199 the specific chemical designation, dextrophan and levopropoxyphene excepted:
- 200 (a) Alfentanil;
 - 201 (b) Alphaprodine;
 - 202 (c) Anileridine;
 - 203 (d) Bezitramide;
 - 204 (e) Bulk Dextropropoxyphene;
 - 205 (f) Carfentanil;
 - 206 (g) Butyl nitrite;
 - 207 (h) Dihydrocodeine;
 - 208 (i) Diphenoxylate;
 - 209 (j) Fentanyl;
 - 210 (k) Isomethadone;
 - 211 (l) Levo-alphacetylmethadol;
 - 212 (m) Levomethorphan;
 - 213 (n) Levorphanol;
 - 214 (o) Metazocine;
 - 215 (p) Methadone;
 - 216 (q) Meperidine;
 - 217 (r) Methadone-Intermediate, 4-cyano-2-dimethylamino-4, 4-diphenylbutane;
 - 218 (s) Moramide-Intermediate, 2-methyl-3-morpholino-1, 1-diphenylpropane--carboxylic
 - 219 acid;
 - 220 (t) Pethidine;
 - 221 (u) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine;
 - 222 (v) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate;
 - 223 (w) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic acid;
 - 224 (x) Phenazocine;
 - 225 (y) Piminodine;
 - 226 (z) Racemethorphan;
 - 227 (aa) Racemorphan;
 - 228 (bb) Sulfentanil;
 - 229 (3) Any material, compound, mixture, or preparation which contains any quantity of the
 - 230 following substances having a stimulant effect on the central nervous system:
 - 231 (a) Amphetamine, its salts, optical isomers, and salts of its optical isomers;

232 (b) Methamphetamine, its salts, isomers, and salts of its isomers;
233 (c) Phenmetrazine and its salts;
234 (d) Methylphenidate;
235 (4) Any material, compound, mixture, or preparation which contains any quantity of the
236 following substances having a depressant effect on the central nervous system, including its salts,
237 isomers, and salts of isomers whenever the existence of those salts, isomers, and salts of isomers
238 is possible within the specific chemical designation:
239 (a) Amobarbital;
240 (b) Glutethimide;
241 (c) Pentobarbital;
242 (d) Phencyclidine;
243 (e) Secobarbital;
244 (5) Any material, compound or compound which contains any quantity of the following
245 substances:
246 (a) Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a
247 United States Food and Drug Administration approved drug product;
248 (b) Nabilone;
249 (6) Any material, compound, mixture, or preparation which contains any quantity of the
250 following substances:
251 (a) Immediate precursor to amphetamine and methamphetamine: Phenylacetone;
252 (b) Immediate precursors to phencyclidine (PCP):
253 a. 1-phenylcyclohexylamine;
254 b. 1-piperidinocyclohexanecarbonitrile (PCC).
255 5. The department of health and senior services shall place a substance in Schedule III
256 if it finds that:
257 (1) The substance has a potential for abuse less than the substances listed in Schedules
258 I and II;
259 (2) The substance has currently accepted medical use in treatment in the United States;
260 and
261 (3) Abuse of the substance may lead to moderate or low physical dependence or high
262 psychological dependence.
263 6. The controlled substances listed in this subsection are included in Schedule III:
264 (1) Any material, compound, mixture, or preparation which contains any quantity of the
265 following substances having a potential for abuse associated with a stimulant effect on the
266 central nervous system:
267 (a) Benzphetamine;

- 268 (b) Chlorphentermine;
269 (c) Clortermine;
270 (d) Phendimetrazine;
271 (2) Any material, compound, mixture or preparation which contains any quantity or salt
272 of the following substances or salts having a depressant effect on the central nervous system:
273 (a) Any material, compound, mixture or preparation which contains any quantity or salt
274 of the following substances combined with one or more active medicinal ingredients:
275 a. Amobarbital;
276 b. Gamma hydroxybutyric acid and its salts, isomers, and salts of isomers contained in
277 a drug product for which an application has been approved under Section 505 of the Federal
278 Food, Drug, and Cosmetic Act;
279 c. Secobarbital;
280 d. Pentobarbital;
281 (b) Any suppository dosage form containing any quantity or salt of the following:
282 a. Amobarbital;
283 b. Secobarbital;
284 c. Pentobarbital;
285 (c) Any substance which contains any quantity of a derivative of barbituric acid or its
286 salt;
287 (d) Chlorhexadol;
288 (e) Ketamine, its salts, isomers, and salts of isomers;
289 (f) Lysergic acid;
290 (g) Lysergic acid amide;
291 (h) Methyprylon;
292 (i) Sulfondiethylmethane;
293 (j) Sulfonethylmethane;
294 (k) Sulfonmethane;
295 (l) Tiletamine and zolazepam or any salt thereof;
296 (3) Nalorphine;
297 (4) Any material, compound, mixture, or preparation containing limited quantities of any
298 of the following narcotic drugs or their salts:
299 (a) Not more than 1.8 grams of codeine per one hundred milliliters or not more than
300 ninety milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid
301 of opium;
302 (b) Not more than 1.8 grams of codeine per one hundred milliliters or not more than
303 ninety milligrams per dosage unit with one or more active, nonnarcotic ingredients in recognized

304 therapeutic amounts;

305 (c) Not more than three hundred milligrams of hydrocodone per one hundred milliliters
306 or not more than fifteen milligrams per dosage unit, with a fourfold or greater quantity of an
307 isoquinoline alkaloid of opium;

308 (d) Not more than three hundred milligrams of hydrocodone per one hundred milliliters
309 or not more than fifteen milligrams per dosage unit, with one or more active nonnarcotic
310 ingredients in recognized therapeutic amounts;

311 (e) Not more than 1.8 grams of dihydrocodeine per one hundred milliliters or more than
312 ninety milligrams per dosage unit, with one or more active nonnarcotic ingredients in recognized
313 therapeutic amounts;

314 (f) Not more than three hundred milligrams of ethylmorphine per one hundred milliliters
315 or not more than fifteen milligrams per dosage unit, with one or more active, nonnarcotic
316 ingredients in recognized therapeutic amounts;

317 (g) Not more than five hundred milligrams of opium per one hundred milliliters or per
318 one hundred grams or not more than twenty-five milligrams per dosage unit, with one or more
319 active nonnarcotic ingredients in recognized therapeutic amounts;

320 (h) Not more than fifty milligrams of morphine per one hundred milliliters or per one
321 hundred grams, with one or more active, nonnarcotic ingredients in recognized therapeutic
322 amounts;

323 (5) Anabolic steroids. Unless specially excepted or unless listed in another schedule, any
324 material, compound, mixture or preparation containing any quantity of the following substances,
325 including its salts, isomers and salts of isomers whenever the existence of such salts of isomers
326 is possible within the specific chemical designation:

327 (a) Boldenone;

328 (b) Chlorotestosterone (4-Chlortestosterone);

329 (c) Clostebol;

330 (d) Dehydrochlormethyltestosterone;

331 (e) Dihydrotestosterone (4-Dihydro-testosterone);

332 (f) Drostanolone;

333 (g) Ethylestrenol;

334 (h) Fluoxymesterone;

335 (i) Formebolone (Formebolone);

336 (j) Mesterolone;

337 (k) Methandienone;

338 (l) Methandranone;

339 (m) Methandriol;

- 340 (n) Methandrostenolone;
341 (o) Methenolone;
342 (p) Methyltestosterone;
343 (q) Mibolerone;
344 (r) Nandrolone;
345 (s) Norethandrolone;
346 (t) Oxandrolone;
347 (u) Oxymesterone;
348 (v) Oxymetholone;
349 (w) Stanolone;
350 (x) Stanozolol;
351 (y) Testolactone;
352 (z) Testosterone;
353 (aa) Trenbolone;
354 (bb) Any salt, ester, or isomer of a drug or substance described or listed in this
355 subdivision, if that salt, ester or isomer promotes muscle growth except an anabolic steroid
356 which is expressly intended for administration through implants to cattle or other nonhuman
357 species and which has been approved by the secretary of health and human services for that
358 administration.
- 359 (6) The department of health and senior services may except by rule any compound,
360 mixture, or preparation containing any stimulant or depressant substance listed in subdivisions
361 (1) and (2) of this subsection from the application of all or any part of sections 195.010 to
362 195.320 if the compound, mixture, or preparation contains one or more active medicinal
363 ingredients not having a stimulant or depressant effect on the central nervous system, and if the
364 admixtures are included therein in combinations, quantity, proportion, or concentration that
365 vitiate the potential for abuse of the substances which have a stimulant or depressant effect on
366 the central nervous system.
- 367 7. The department of health and senior services shall place a substance in Schedule IV
368 if it finds that:
- 369 (1) The substance has a low potential for abuse relative to substances in Schedule III;
370 (2) The substance has currently accepted medical use in treatment in the United States;
371 and
- 372 (3) Abuse of the substance may lead to limited physical dependence or psychological
373 dependence relative to the substances in Schedule III.
- 374 8. The controlled substances listed in this subsection are included in Schedule IV:
- 375 (1) Any material, compound, mixture, or preparation containing any of the following

376 narcotic drugs or their salts calculated as the free anhydrous base or alkaloid, in limited quantities
377 as set forth below:

378 (a) Not more than one milligram of difenoxin and not less than twenty-five micrograms
379 of atropine sulfate per dosage unit;

380 (b) Dextropropoxyphene (alpha-(+)-4-dimethy-lamino-1, 2-diphenyl-3-methyl-2-
381 propionoxybutane);

382 (c) Any of the following limited quantities of narcotic drugs or their salts, which shall
383 include one or more nonnarcotic active medicinal ingredients in sufficient proportion to confer
384 upon the compound, mixture or preparation valuable medicinal qualities other than those
385 possessed by the narcotic drug alone:

386 a. Not more than two hundred milligrams of codeine per one hundred milliliters or per
387 one hundred grams;

388 b. Not more than one hundred milligrams of dihydrocodeine per one hundred milliliters
389 or per one hundred grams;

390 c. Not more than one hundred milligrams of ethylmorphine per one hundred milliliters
391 or per one hundred grams;

392 (2) Any material, compound, mixture or preparation containing any quantity of the
393 following substances, including their salts, isomers, and salts of isomers whenever the existence
394 of those salts, isomers, and salts of isomers is possible within the specific chemical designation:

395 (a) Alprazolam;

396 (b) Barbitol;

397 (c) Bromazepam;

398 (d) Camazepam;

399 (e) Chloral betaine;

400 (f) Chloral hydrate;

401 (g) Chlordiazepoxide;

402 (h) Clobazam;

403 (i) Clonazepam;

404 (j) Clorazepate;

405 (k) Clotiazepam;

406 (l) Cloxazolam;

407 (m) Delorazepam;

408 (n) Diazepam;

409 (o) Estazolam;

410 (p) Ethchlorvynol;

411 (q) Ethinamate;

412 (r) Ethyl loflazepate;
413 (s) Fludiazepam;
414 (t) Flunitrazepam;
415 (u) Flurazepam;
416 (v) Halazepam;
417 (w) Haloxazolam;
418 (x) Ketazolam;
419 (y) Loprazolam;
420 (z) Lorazepam;
421 (aa) Lormetazepam;
422 (bb) Mebutamate;
423 (cc) Medazepam;
424 (dd) Meprobamate;
425 (ee) Methohexital;
426 (ff) Methylphenobarbital;
427 (gg) Midazolam;
428 (hh) Nimetazepam;
429 (ii) Nitrazepam;
430 (jj) Nordiazepam;
431 (kk) Oxazepam;
432 (ll) Oxazolam;
433 (mm) Paraldehyde;
434 (nn) Petrichloral;
435 (oo) Phenobarbital;
436 (pp) Pinazepam;
437 (qq) Prazepam;
438 (rr) Quazepam;
439 (ss) Temazepam;
440 (tt) Tetrazepam;
441 (uu) Triazolam;
442 (vv) Zolpidem;

443 (3) Any material, compound, mixture, or preparation which contains any quantity of the
444 following substance including its salts, isomers and salts of isomers whenever the existence of
445 such salts, isomers and salts of isomers is possible: fenfluramine;

446 (4) Any material, compound, mixture or preparation containing any quantity of the
447 following substances having a stimulant effect on the central nervous system, including their

448 salts, isomers and salts of isomers:

- 449 (a) Cathine ((+)-norpseudoephedrine);
- 450 (b) Diethylpropion;
- 451 (c) Fencamfamin;
- 452 (d) Fenproporex;
- 453 (e) Mazindol;
- 454 (f) Mefenorex;
- 455 (g) Pemoline, including organometallic complexes and chelates thereof;
- 456 (h) Phentermine;
- 457 (i) Pipradrol;
- 458 (j) SPA ((-)-1-dimethylamino-1,2-diphenylethane);

459 (5) Any material, compound, mixture or preparation containing any quantity of the
460 following substance, including its salts: pentazocine;

461 (6) Any material, compound, mixture or preparation which contains any quantity of the
462 following substances having a stimulant effect on the central nervous system including their
463 salts, isomers and salts of isomers: ephedrine or its salts, optical isomers, or salts of optical
464 isomers as the only active medicinal ingredient or contains ephedrine or its salts, optical isomers,
465 or salts of optical isomers and therapeutically insignificant quantities of another active medicinal
466 ingredient;

467 (7) The department of health and senior services may except by rule any compound,
468 mixture, or preparation containing any depressant substance listed in subdivision (1) of this
469 subsection from the application of all or any part of sections 195.010 to 195.320 if the
470 compound, mixture, or preparation contains one or more active medicinal ingredients not having
471 a depressant effect on the central nervous system, and if the admixtures are included therein in
472 combinations, quantity, proportion, or concentration that vitiate the potential for abuse of the
473 substances which have a depressant effect on the central nervous system.

474 9. The department of health and senior services shall place a substance in Schedule V
475 if it finds that:

476 (1) The substance has low potential for abuse relative to the controlled substances listed
477 in Schedule IV;

478 (2) The substance has currently accepted medical use in treatment in the United States;
479 and

480 (3) The substance has limited physical dependence or psychological dependence liability
481 relative to the controlled substances listed in Schedule IV.

482 10. The controlled substances listed in this subsection are included in Schedule V:

483 (1) Any material, compound, mixture or preparation containing any of the following

484 narcotic drug and its salts: buprenorphine;

485 (2) Any compound, mixture or preparation containing any of the following narcotic
486 drugs or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set
487 forth below, which also contains one or more nonnarcotic active medicinal ingredients in
488 sufficient proportion to confer upon the compound, mixture or preparation valuable medicinal
489 qualities other than those possessed by the narcotic drug alone:

490 (a) Not more than two and five-tenths milligrams of diphenoxylate and not less than
491 twenty-five micrograms of atropine sulfate per dosage unit;

492 (b) Not more than one hundred milligrams of opium per one hundred milliliters or per
493 one hundred grams;

494 (c) Not more than five-tenths milligram of difenoxin and not less than twenty-five
495 micrograms of atropine sulfate per dosage unit;

496 (3) Any material, compound, mixture or preparation which contains any quantity of the
497 following substance having a stimulant effect on the central nervous system including its salts,
498 isomers and salts of isomers: pyrovalerone.

499 11. The department of health and senior services shall revise and republish the schedules
500 annually.